IRVINE, Calif., July 1, 2013 /PRNewswire/ -- ChromaDex Corp. ® (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with The Scripps Research Institute ("TSRI") whereby ChromaDex will provide TSRI with quantities of its recently launched Niagen™ nicotinamide riboside (NR). TSRI researchers have been studying the relationship between dysfunction of mitochondria, the energy-producing parts of the cell, and various life-threatening diseases. More specifically, the studies have focused on whether disease-affected cells change the balance between nicotinamide adenine dinucleotide, or NAD+, which has a positive charge, and NADH, an electrically neutral form of the molecule. TSRI research has shown that therapeutic normalization of the NAD+/NADH balance can prevent the disease progression. The results translate into a new therapeutic strategy: enhancement of the NAD+/NADH balance through treatment with NAD+ precursors, such as nicotinamide riboside. Commenting on the announcement, Frank Jaksch, ChromaDex founder and CEO, states "We are pleased to partner with TSRI on such important and exciting research. Their studies will add to the growing amount of research showing of the important health benefits of nicotinamide riboside, and portends one of the possible pharmaceutical uses for Niagen™." ChromaDex's Niagen™ has the potential to be a next generation Niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products. Niagen™ is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market. AboutNicotinamide Riboside (NR): Sometimes referred to as the "Miracle Molecule" or the "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). The beneficial effects of NR in humans include increased fatty acid oxidation, mitochondrial activity, resistance to the negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and the blocking muscle degeneration.